Skip to main content
NASDAQ:CYTH

Cyclo Therapeutics News Headlines

$7.26
+0.26 (+3.71 %)
(As of 05/17/2021 11:00 AM ET)
Add
Compare
Today's Range
$7.07
$7.26
50-Day Range
$6.58
$9.27
52-Week Range
$3.55
$17.75
Volume528 shs
Average Volume826,340 shs
Market Capitalization$46.17 million
P/E RatioN/A
Dividend YieldN/A
Beta-1

Headlines

Cyclo Therapeutics (NASDAQ CYTH) News Headlines Today

SourceHeadline
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial ResultsCyclo Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 17 at 11:29 AM
Cyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient AdvocacyCyclo Therapeutics Appoints Lori McKenna Gorski as Global Head of Patient Advocacy
finance.yahoo.com - May 11 at 10:16 AM
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1
finance.yahoo.com - April 27 at 12:26 PM
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s DiseaseCyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease
finance.yahoo.com - April 20 at 1:38 PM
Tuesday 4/13 Insider Buying Report: TPL, CYTHTuesday 4/13 Insider Buying Report: TPL, CYTH
nasdaq.com - April 13 at 1:02 PM
Cyclo Therapeutics Stock Gives Every Indication Of Being Possible Value TrapCyclo Therapeutics Stock Gives Every Indication Of Being Possible Value Trap
finance.yahoo.com - April 7 at 11:19 PM
Cyclo Therapeutics Trappsol Phase 1/2 Trial In Niemann-Pick Type C1 Patients Meets EndpointsCyclo Therapeutics' Trappsol Phase 1/2 Trial In Niemann-Pick Type C1 Patients Meets Endpoints
nasdaq.com - March 25 at 2:48 PM
Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)
finance.yahoo.com - March 25 at 9:48 AM
Cyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial ResultsCyclo Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 15 at 12:41 PM
Cyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual ConferenceCyclo Therapeutics to Participate in Inaugural Emerging Growth Virtual Conference
finance.yahoo.com - March 12 at 3:14 PM
Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol ...Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol ...
businesswire.com - March 10 at 1:48 PM
Cyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial OfficerCyclo Therapeutics Appoints Russ Belden as Acting Chief Commercial Officer
finance.yahoo.com - March 10 at 1:48 PM
Cyclo Gets Positive Opinion From EMA Committee On Agreement Of PIP For Trappsol Cyclo; Stock UpCyclo Gets Positive Opinion From EMA Committee On Agreement Of PIP For Trappsol Cyclo; Stock Up
markets.businessinsider.com - March 9 at 9:36 AM
Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™Cyclo Therapeutics Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric Investigation Plan for Trappsol® Cyclo™
finance.yahoo.com - March 9 at 9:36 AM
Cyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type CCyclo Therapeutics Announces Last Patient Last Visit in Phase 1/2 Trial Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
finance.yahoo.com - March 4 at 12:53 PM
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical OfficerCyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer
finance.yahoo.com - March 1 at 9:51 AM
Cyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and FamiliesCyclo Therapeutics Unveils New Corporate Identity and Reaffirms Commitment to Improving Quality of Life and Providing Hope for Patients and Families
finance.yahoo.com - February 22 at 1:36 PM
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, TrappsolCyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol
businesswire.com - February 10 at 8:15 PM
Stock Alert: Cyclo Therapeutics Adds 20% Following Positive Data From Drug CandidateStock Alert: Cyclo Therapeutics Adds 20% Following Positive Data From Drug Candidate
nasdaq.com - February 9 at 1:33 PM
Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
finance.yahoo.com - February 9 at 8:33 AM
Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021Cyclo Therapeutics to Present on Its Clinical and Drug Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021
finance.yahoo.com - January 26 at 8:48 AM
Cyclo Therapeutics, Inc. (CYTH)Cyclo Therapeutics, Inc. (CYTH)
finance.yahoo.com - January 5 at 10:45 PM
Why Cyclo, Vivos Therapeutics And More Are Moving TodayWhy Cyclo, Vivos Therapeutics And More Are Moving Today
msn.com - January 5 at 5:45 PM
Stock Alert: Cyclo Therapeutics Zooms 45%Stock Alert: Cyclo Therapeutics Zooms 45%
nasdaq.com - January 5 at 12:44 PM
Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type CCyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type C
finance.yahoo.com - January 5 at 12:44 PM
Cyclo Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares of Common Stock in Connection with its Underwritten Public OfferingCyclo Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares of Common Stock in Connection with its Underwritten Public Offering
finance.yahoo.com - December 22 at 5:37 PM
Cyclo Therapeutics Inc.Cyclo Therapeutics Inc.
wsj.com - December 20 at 1:07 AM
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.